Biotech Company** (Country) | Pharma Company (Symbol/Country) | Type/Product Area | Amount | Terms/Details (Month) |
I. MODIFIED AGREEMENTS | ||||
Abgenix Inc. | Pfizer Inc. (NYSE:PFE) | Expansion of 12/97 collaboration and license agreement on use of Abgenix'sXenoMouse technology to make fully human antibodies to 3 of Pfizer's antigentargets | $10M | Pfizer exercised option for 2nd antigen target (undisclosed; 1st targetis for oncology applications); with exercise of option, Abgenix gets $10Min cash plus royalties (10/98) |
Allelix Biopharmaceuticals Inc. (Canada) | Eli Lilly and Co. (NYSE:LLY) | Extension and expansion of partnership dating from 1989 on productsfor treating psychiatric, neurological and eating disorders | ND | Glutamate receptor program (for psychiatric and neurological disorders)has been extended for 2 years; genetic target program (for eating disorders)has been extended for 1 year (12/98) |
ArQule Inc. | Roche Bioscience (division of Roche Holding Ltd.; Switzerland) | Amendment to 9/96 collaboration on new therapeutics via ArQule's directedarrays (custom libraries of compounds closely analogous to leads providedby Roche Bioscience) | ND | Companies will continue collaboration in a different form (not defined)through 3/99; ArQule will provide Roche with screening libraries whilecontinuing to optimize a number of Roche compounds (10/98) |
Axys Pharmaceuticals Inc. | Merck & Co. Inc. (NYSE:MRK) | Extension of 11/96 collaboration on small molecule inhibitors of cathepsinK (cysteine protease) as therapies for osteoporosis | ND | Original agreement signed with Arris Pharmaceutical Corp. (which mergedwith Sequana Therapeutics Inc. in 1/98 to form Axys); companies extendedcollaboration to 11/99; further details ND (12/98) |
Corixa Corp. | SmithKline Beecham | Major expansion of 10/95 | $200M | Expanded agreement adds 5 new vaccine |
Biologicals SA | collaboration on T cell- | (equity; | programs; SmithKline also has option to | |
(Belgium; unit of | active vaccines for tuber- | % ND) | select 1 more application in future; 4-year | |
SmithKline Beecham | culosis (amended 3/97 to | collaboration; SmithKline licensed rights | ||
plc; NYSE:SBH; U.K.) | include antigens for use in | to Corixa's HER-2/neu vaccine for breast | ||
vaccines for breast and | and ovarian cancer and its breast cancer | |||
prostate cancer) to include | antigen mammaglobin; except for tuber- | |||
vaccines for ovarian and | culosis vaccine, SmithKline gets exclusive | |||
colon carcinoma as well as | worldwide rights to all vaccine products; | |||
for infectious diseases | SmithKline also has option on nonexclusive | |||
Chlamydia trachomatis | license to Corixa's LeiF adjuvant and its | |||
and C. pneumoniae | microsphere delivery technology; Corixa | |||
gets $49M committed funding over 4 years | ||||
(which includes a $2.5M equity purchase | ||||
now and $2.5M in the future, both at premi- | ||||
um); Corixa gets milestones of $150M, as | ||||
well as royalties; Corixa retains right to | ||||
form non-vaccine partnerships for these | ||||
antigens; transaction subject to antitrust | ||||
considerations (10/98) | ||||
Corvas | Ortho Clinical | Restructured agreement | $1M | Original 1992 agreement concerned |
International Inc. | Diagnostics Inc. | that supercedes 1992 | supply of thromboplastin formulations | |
(unit of Johnson & | agreement for license to | to Ortho; Corvas has now licensed the | ||
Johnson; NYSE:JNJ) | Corvas' recombinant | diagnostic applications of its thrombo- | ||
thromboplastin for use | plastin; Ortho also gets certain licenses | |||
in diagnostics | related to production of recombinant | |||
tissue factor; Corvas gets $1M for | ||||
these licenses and will continue to get | ||||
royalties (12/98) | ||||
Schering-Plough | Extension of 6/97 | $3M | Schering-Plough will support preclinical | |
Corp. (NYSE:SGP) | collaboration on oral | development through 9/99 and provide | ||
anticoagulants based on | additional $3M in funding (12/98) | |||
protease inhibitors | ||||
Gene Logic Inc. | The Procter & | Expansion of 6/97 | ND | Expansion will result in doubling of |
Gamble Co. | collaboration on thera- | Gene Logic's annual revenues from | ||
(NYSE:PG) | peutic targets for heart | collaboration; Procter & Gamble gets | ||
failure (via Gene Logic's | access to databases and will pay annual | |||
READS gene expression | fees; Gene Logic also gets milestones | |||
technology for database of | and royalties; the partners can now | |||
differential gene expres- | work together on any disease indication; | |||
sion) to include target in | Gene Logic can work with 3rd parties | |||
osteoporosis | on specific indications (12/98) | |||
Rhone-Poulenc | Expansion of 9/97 | ND | The original agreement was between | |
Rorer Inc. | alliance to conduct p53 | Rhone-Poulenc Rorer and OncorMed | ||
(subsidiary of | testing for clinical trials | (which Gene Logic acquired in 9/98); | ||
Rhone-Poulenc SA; | of adenoviral p53 gene | this is expansion of alliance to analyze | ||
NYSE:RP; France) | therapy for cancer | genes for gene therapy clinical trials; | ||
financial details ND (11/98) | ||||
GeneMedicine Inc. | Merck & Co. Inc. | Expansion of 12/97 | ND | Collaboration initially focused on 2 |
(NYSE:MRK) | collaboration to evaluate | therapeutic applications; it has now been | ||
GeneMedicine's Gene- | expanded to include 3 applications; | |||
Switch technology (to | further details ND (11/98) | |||
control gene expression) | ||||
with Merck's vector system | ||||
for gene-based therapies | ||||
Genome | Schering-Plough | Acceleration of 12/96 | ND | Asthma genetics program is ahead of |
Therapeutics | Corp. (NYSE:SGP) | collaboration to identify | schedule; companies have enlarged | |
Corp. | genes involved in suscep- | program substantially and have moved | ||
tibility to asthma | up the time lines (11/98) | |||
Incyte Pharma- | Pfizer Inc. | Expansion of 6/94 genom- | ND | Companies already extended and |
ceuticals Inc. | (NYSE:PFE) | ic database partnership to | expanded agreement in 2/98; now, | |
include Incyte's LifeTools | Pfizer will use Incyte's LifeTools and | |||
bioinformatics software | LifeArray to support its global research | |||
and LifeArray microarray | programs; details ND (9/98) | |||
data analysis and manage- | ||||
ment software | ||||
Inhale Therapeutic | Baxter International | Amendment of terms of | ND | Companies intend to find 3rd party to |
Systems Inc. | Inc. (NYSE:BAX) | 3/96 collaboration to use | further develop and commercialize | |
Inhale's dry-powder pul- | an undisclosed compound; Baxter will | |||
monary delivery system | continue to provide funding in prepara- | |||
for non-peptide, non- | tion for Phase II trials while 3rd party | |||
protein drug candidates | is identified; product falls outside Bax- | |||
ter's current business focus; other 2 | ||||
compounds in collaboration will remain | ||||
and may be developed in future (10/98) | ||||
Medarex Inc. | Merck KGaA | Option to expand 4/94 | $1.5M | Merck paid $1.5M to obtain exclusive |
(Germany) | collaboration on Meda- | option on worldwide licensing rights to | ||
rex's MDX-477 bispecific | product; Medarex would retain U.S. | |||
antibody for certain cancers | rights; Merck will fully fund Phase II | |||
(targets epidermal growth | trials (12/98) | |||
factor receptor; currently | ||||
in Phase II trials for head | ||||
and neck cancer) | ||||
Microcide | Ortho-McNeil | Extension of 10/95 collab- | ND | Companies will continue joint develop- |
Pharmaceuticals | Pharmaceuticals and | oration on therapeutics for | ment of beta-lactam compounds; John- | |
Inc. | the R.W. Johnson | Gram-positive bacterial | son & Johnson will support research | |
Pharmaceutical | infections, especially drug- | for additional 8-14 months; the duration | ||
Research Institute | resistant strains; focus on | and amount of funding will depend on | ||
(units of Johnson & | beta-lactam compounds | selection of 1 additional compound for | ||
Johnson; NYSE:JNJ) | development by 12/31/98; Microcide | |||
regained rights to its antibiotic potentia- | ||||
tor technologies and compounds (10/98) | ||||
Myriad Genetics | Bayer Corp. | Extension of 9/95 alliance | $12.2M | Bayer extended collaboration until 9/02; |
Inc. | (unit of Bayer AG; | to discover genes that | Myriad has made significant progress | |
Germany) | predispose individuals to | toward isolating disease-causing genes; | ||
obesity, osteoporosis and | Myriad will get additional $6.2M in | |||
asthma | committed research funds plus $6M in | |||
milestones over next 2 years (12/98) | ||||
Neurogen Corp. | Pfizer Inc. | Extension and expansion | $12.5M | Collaboration extended for 2 years; |
(NYSE:PFE) | of collaborations on small- | Neurogen gets $6.25M per year in | ||
molecule drugs that act on | additional research funds (11/98) | |||
specific GABA receptors | ||||
in brain; on drugs for | ||||
anxiety and cognition | ||||
(from 2/92) and drugs for | ||||
sleep disorders (from 6/94); | ||||
added depression as new | ||||
target | ||||
Xenova Group | Parke-Davis | Extension of 5/97 drug | ND | Xenova provided natural product extracts |
plc (U.K.) | (division of | discovery collaboration | for screening, which Parke-Davis has done, | |
Warner-Lambert | based on Xenova's | identifying potential hits from which | ||
Co.; NYSE:WLA) | NatChem natural products | Xenova will now isolate and identify | ||
library | active chemicals; Xenova gets certain | |||
additional payments (10/98) | ||||
II. TERMINATED AGREEMENTS | ||||
Alkermes Inc. | The R.W. Johnson | Termination of 12/96 | Companies reached mutual decision to | |
Pharmaceutical | collaboration on use of | terminate collaboration; Alkermes | ||
Research Institute | Alkermes' ProLease drug | regains all rights licensed to Pharma- | ||
(unit of Johnson & | delivery system to develop | ceutical Research Institute, which has | ||
Johnson; NYSE:JNJ) | sustained-release formula- | discontinued product development | ||
tion of undisclosed drug | (11/98) | |||
for treating hormone- | ||||
mediated disorders | ||||
Schering-Plough | Termination of 1/92 | Companies reached mutual decision | ||
Corp. (NYSE:SGP) | agreement on use of | to terminate collaboration; Alkermes | ||
Alkermes' ProLease drug | regains all rights licensed to Schering- | |||
delivery system to develop | Plough; further details ND (11/98) | |||
sustained-release formula- | ||||
tion of Intron A (recombi- | ||||
nant interferon alfa-2b) | ||||
Allelix Biopharma- | Astra AB | Termination of 6/96 | As a result of corporate restructuring | |
ceuticals Inc. | (Sweden) | agreement to develop | at Astra, this program no longer fits; | |
(Canada) | ALX1-11 (recombinant | Allelix reacquired all product rights, | ||
human parathyroid | including assets, know-how and pro- | |||
hormone) for treating | prietary rights; Allelix will assume | |||
osteoporosis (currently | responsibility for product development | |||
in Phase II trials) | (9/98) | |||
Ergo Science | The R.W. Johnson | Termination of 2/98 | FDA denied approval of Ergoset in | |
Corp. | Pharmaceutical | collaboration on | 11/98, after which Johnson & Johnson | |
Research Institute | Ergoset Tablets (bromo- | terminated collaboration (12/98) | ||
and Ortho-McNeil | criptine mesylate; dopa- | |||
Pharmaceutical Inc. | mine agonist) and other | |||
(units of Johnson | products for treating | |||
& Johnson; NYSE:JNJ) | Type II diabetes and | |||
obesity | ||||
Inex Pharma- | Schwarz Pharma | Termination of 3/98 | Drug failed to show benefit in Phase II | |
ceuticals Corp. | AG (Germany) | collaboration to develop | trial; companies discontinued develop- | |
(TSE:IEX; Canada) | antisense drug INX-3280 | ment in Europe and North America; | ||
(blocks function of c-myc | Inex will not continue product develop- | |||
gene) for treating cardio- | ment on its own (10/98) | |||
vascular restenosis | ||||
Intercardia Inc. | Astra Pharma- | Termination of 12/95 | As a result of corporate restructuring at | |
ceuticals LP | agreement on Bextra | Astra (it bought out Merck's share of Astra | ||
(formerly Astra | (bucindolol HCl) for | Merck), Astra's product line now includes | ||
Merck Inc.) | treating congestive heart | a competing product (Toprol-XL); agreement | ||
failure (currently in | terminated by mutual agreement, due to | |||
Phase III trials) | non-compete clause in terms of original | |||
deal; Intercardia regains all rights, material | ||||
and information relating to product, | ||||
plus termination fee (9/98) | ||||
NeoRx Corp. | Janssen | Termination of 8/97 | Janssen will terminate agreement at | |
Pharmaceutica NV | collaboration on NeoRx's | year-end 1998, but is currently com- | ||
(Belgium; unit of | radioimmunotherapy prod- | pleting Phase II trials in advanced | ||
Johnson & Johnson; | uct Avicidin (for treating | colon and prostate cancer; patients | ||
NYSE:JNJ) | solid tumors) | exhibited high incidence of unaccept- | ||
able diarrhea; all rights to product and | ||||
underlying pretargeting technology | ||||
revert to NeoRx, along with all data | ||||
generated by study (9/98) | ||||
Schwarz Pharma | Termination of 4/97 | Schwarz ceased product development, | ||
AG (Germany) | collaboration on NeoRx's | citing need for more studies with a new | ||
Biostent (combination | catheter and delays in the project; | |||
drug/device) for treating | NeoRx has no plans to conduct Phase II | |||
restenosis following | trials without a partner (11/98) | |||
balloon angioplasty | ||||
(Phase I trials completed) | ||||
Sonus Pharma- | Daiichi | Termination of 3/95 | Daiichi took product through Phase I | |
ceuticals Inc. | Pharmaceutical | license agreement on | trials in Japan, completed in 12/97, but | |
Co. Ltd. (Japan) | EchoGen ultrasound | no further clinical development since | ||
contrast agent for intra- | that time; Sonus terminated agreement | |||
venous myocardial con- | and is seeking another development | |||
trast echocardiography | partner (11/98) | |||
NOTES: | ||||
# This chart contains information on modified and terminatedagreements only, covering the time period between 9/23/98 and 12/24/98.It does not include arrangements that are classed strictly as production,marketing and/or distribution agreements, nor does it include any collaborationsthat involve agricultural product development. | ||||
For a chart listing new collaborations between biotechcompanies and big pharma for the same time period (9/23/98 12/24/98),see the 1/4/99 issue of BioWorld Financial Watch. | ||||
ND = Not disclosed, reported and/or available; TSE = TorontoStock Exchange | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise notes, the trading symbols for publicbiotechnology companies can be found by referring to the BioWorld Stockreport For Public Biotechnology Companies on pp. 12-13. |